First oral Wegovy weight-loss pill moves closer to European approval

COPENHAGEN: Novo Nordisk has moved a major step closer to bringing the first oral weight-loss medicine to patients across Europe after the European Medicines Agency (EMA) recommended approval of its Wegovy tablet, a decision that could reshape obesity treatment by offering a needle-free alternative to injectable therapies.

The recommendation positions Novo Nordisk ahead of rival Eli Lilly in the race to expand access to obesity medicines through oral formulations, an area increasingly viewed as the next major battleground in the global weight-management market.

If granted final authorization by the European Commission, the tablet version of Wegovy would become the first approved oral obesity treatment in the European Union, offering patients a new option beyond injectable medications.

What is the oral Wegovy pill?

The oral version of Wegovy contains semaglutide, the same active ingredient used in Novo Nordisk’s blockbuster injectable drugs Wegovy, prescribed for obesity, and Ozempic, used in the treatment of type 2 diabetes.

Semaglutide belongs to a class of medicines known as GLP-1 receptor agonists, which help regulate appetite, increase feelings of fullness, and reduce food intake. These therapies have transformed obesity management worldwide by delivering clinically significant weight loss while also improving several obesity-related health risks.

While injectable GLP-1 drugs have seen unprecedented demand in recent years, many experts believe oral formulations could further expand access by attracting patients reluctant to use injections.

Clinical trial results show significant weight loss

The EMA's recommendation was supported by late-stage clinical trial data demonstrating substantial weight reduction among participants taking the medication.

According to the regulator, patients receiving a 25-milligram daily dose of oral Wegovy achieved an average 16.6% reduction in body weight over 64 weeks, compared with 2.7% among participants receiving placebo treatment.

The results reinforce growing evidence that oral GLP-1 therapies may offer effectiveness approaching that of some injectable obesity medications.

Why the decision matters

Obesity has emerged as one of the world's most pressing public health challenges, with rates continuing to rise across both developed and developing countries.

Medical experts increasingly view obesity as a chronic disease linked to numerous serious health conditions, including:

• Type 2 diabetes
• Cardiovascular disease
• Hypertension
• Sleep apnea
• Certain cancers
• Musculoskeletal disorders

The availability of oral treatment options may improve patient acceptance and long-term adherence, particularly among individuals who are hesitant to begin injectable therapy.

The EMA noted that tablet-based treatment may be more convenient for some patients, potentially helping broaden access to evidence-based obesity care.

Competition between Novo Nordisk and Eli Lilly intensifies

The recommendation comes amid escalating competition between Novo Nordisk and Eli Lilly, the two pharmaceutical companies currently dominating the global obesity drug sector.

Analysts estimate that the obesity treatment market could exceed US$100 billion annually within the next decade as demand continues to grow and new therapies reach patients.

Novo Nordisk gained an early advantage after securing US approval for oral Wegovy earlier this year. Eli Lilly has also entered the oral obesity treatment market following the US approval and launch of its weight-loss pill, Foundayo, while European regulatory review remains ongoing.

Industry observers believe oral medications could unlock a significantly larger patient population than injectable treatments by lowering barriers to treatment initiation.

Access challenges may remain

Despite the positive regulatory milestone, experts caution that approval alone may not guarantee widespread patient access across Europe.

Healthcare reimbursement systems differ significantly between European countries, and access to obesity medications often depends on national funding policies, specialist referral requirements, and healthcare budgets.

Experts note that injectable Wegovy remains subject to varying access restrictions in several European markets, meaning the rollout of the oral version may also depend on local reimbursement decisions after approval.

Final approval pending

The EMA's positive opinion will now be reviewed by the European Commission, which is responsible for granting final marketing authorization across the European Union.

The agency also recommended approval of a higher 7.2 mg injectable Wegovy dose delivered through a single pen device, further expanding treatment options within Novo Nordisk’s obesity portfolio.

Novo Nordisk has indicated that it plans to introduce the oral Wegovy tablet in selected markets outside the United States during the second half of 2026, subject to regulatory approvals.

The decision marks another milestone in the rapid evolution of obesity medicine, as pharmaceutical companies increasingly focus on making highly effective weight-loss therapies more accessible, convenient, and scalable for millions of patients worldwide.

---

Stay informed, stay alert

CLICK HERE TO JOIN Medical News Pakistan on WhatsApp for real-time health alerts, expert insights, and breakthrough medical discoveries.